Other research analysts also recently issued reports about the stock. BTIG Research increased their target price on shares of Orthopediatrics to $37.00 and gave the company a “buy” rating in a research report on Wednesday, January 2nd. Zacks Investment Research raised shares of Orthopediatrics from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a research report on Wednesday, January 2nd. Finally, JMP Securities initiated coverage on shares of Orthopediatrics in a research report on Wednesday, February 20th. They set an “outperform” rating and a $44.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $41.00.
NASDAQ:KIDS traded up $0.68 on Tuesday, hitting $41.62. The stock had a trading volume of 402 shares, compared to its average volume of 67,729. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.77 and a current ratio of 10.54. The firm has a market cap of $598.16 million, a price-to-earnings ratio of -43.35 and a beta of 0.04. Orthopediatrics has a 1 year low of $18.50 and a 1 year high of $47.82.
A number of large investors have recently added to or reduced their stakes in KIDS. Sigma Planning Corp bought a new stake in shares of Orthopediatrics during the 1st quarter valued at about $280,000. Rhumbline Advisers raised its holdings in Orthopediatrics by 6.6% in the first quarter. Rhumbline Advisers now owns 9,350 shares of the company’s stock worth $414,000 after buying an additional 580 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in Orthopediatrics by 83,150.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,665 shares of the company’s stock worth $74,000 after buying an additional 1,663 shares during the last quarter. Perkins Capital Management Inc. purchased a new position in Orthopediatrics in the first quarter worth about $221,000. Finally, Conestoga Capital Advisors LLC purchased a new position in shares of Orthopediatrics during the first quarter valued at approximately $440,000. Institutional investors and hedge funds own 44.88% of the company’s stock.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Featured Story: The Structure of a Futures Contract
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.